Medicare Enrolled

Dr. Vadim Zarubin, MD

Hematology & Oncology · Jersey City, NJ
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
377 JERSEY AVE STE 160, Jersey City, NJ 07302
2013338248
In practice since 2014 (11 years)
NPI: 1790188050 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Zarubin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Zarubin? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Zarubin

Dr. Vadim Zarubin is a hematology & oncology specialist in Jersey City, NJ, with 11 years of NPI registration. Based on federal Medicare data, Dr. Zarubin performed 220 Medicare services across 122 unique beneficiaries.

Between the years covered by Open Payments, Dr. Zarubin received a total of $9,674 from 73 pharmaceutical and/or device companies across 593 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Zarubin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 11 years in practice ▲ 220 Medicare services $9,674 industry payments

Medicare Practice Summary

Medicare Utilization ↗
220
Medicare services
Bottom 10% in NJ for hematology & oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
122
Unique beneficiaries
$89
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~20 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
183 $81 $181
New patient office visit, complex (60-74 min) 21 $140 $416
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
16 $118 $231
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$9,674
Total received (2018-2024)
Avg $1,382/year across 7 years
Top 29% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
73
Companies
593
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,525 (98.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$149 (1.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$216
2023
$44
2022
$1,061
2021
$2,675
2020
$2,155
2019
$2,685
2018
$839

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$125
Eisai Inc.
$25
Janssen Biotech, Inc.
$24
Janssen Pharmaceuticals, Inc
$22
Merck Sharp & Dohme LLC
$20
Top 3 companies account for 80.4% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$870
Merck Sharp & Dohme Corporation
$841
AstraZeneca Pharmaceuticals LP
$833
Amgen Inc.
$585
Janssen Biotech, Inc.
$554
E.R. Squibb & Sons, L.L.C.
$495
PFIZER INC.
$453
Celgene Corporation
$377
GENZYME CORPORATION
$308
Astellas Pharma US Inc
$301
Genentech USA, Inc.
$256
Lilly USA, LLC
$243
Bayer HealthCare Pharmaceuticals Inc.
$241
Seagen Inc.
$229
Exelixis Inc.
$213
Incyte Corporation
$185
Pharmacyclics LLC, An AbbVie Company
$146
Puma Biotechnology, Inc.
$143
BeiGene USA, Inc.
$140
EISAI INC.
$134
Daiichi Sankyo Inc.
$129
Kyowa Kirin, Inc.
$127
Teva Pharmaceuticals USA, Inc.
$117
SANOFI-AVENTIS U.S. LLC
$115
Eisai Inc.
$95
GlaxoSmithKline, LLC.
$88
Regeneron Healthcare Solutions, Inc.
$87
Epizyme, Inc.,
$85
Boehringer Ingelheim Pharmaceuticals, Inc.
$85
Merck Sharp & Dohme LLC
$78
Takeda Pharmaceuticals U.S.A., Inc.
$71
Horizon Therapeutics plc
$69
TerSera Therapeutics LLC
$58
Kite Pharma, Inc.
$54
Gilead Sciences, Inc.
$54
Dova Pharmaceuticals
$53
Myovant Sciences Inc.
$45
TESARO, Inc.
$42
Ipsen Biopharmaceuticals, Inc
$40
Roche Diagnostics Corporation
$39
Janssen Pharmaceuticals, Inc
$35
Novocure Inc.
$31
Foundation Medicine, Inc.
$30
Rigel Pharmaceuticals, Inc.
$30
Heron Therapeutics, Inc.
$29
Immunomedics, Inc.
$29
Alexion Pharmaceuticals, Inc.
$25
AVEO Pharmaceuticals, Inc.
$25
Myriad Genetic Laboratories, Inc.
$21
Octapharma USA, Inc.
$18
MACROGENICS, INC.
$16
Coherus Biosciences Inc.
$16
Sun Pharmaceutical Industries Inc.
$16
Jazz Pharmaceuticals Inc.
$16
Servier Pharmaceuticals LLC
$15
SERVIER PHARMACEUTICALS LLC
$15
ARRAY BIOPHARMA INC
$15
Blueprint Medicines Corporation
$15
Seattle Genetics, Inc.
$15
Organon LLC
$15
TG THERAPEUTICS, INC.
$15
JAZZ PHARMACEUTICALS INC.
$15
Advanced Accelerator Applications
$15
AMAG Pharmaceuticals, Inc.
$14
Mylan Institutional Inc.
$14
Otsuka America Pharmaceutical, Inc.
$14
TOLMAR Pharmaceuticals, Inc.
$14
Acceleron Pharma, Inc.
$14
AbbVie Inc.
$13
EMD Serono, Inc.
$12
Secura Bio, Inc.
$12
Lexicon Pharmaceuticals, Inc.
$11
Fortovia Therapeutics, Inc.
$10
Top 3 companies account for 26.3% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ALIMTA · AVSOLA · Abraxane · Alecensa · Avastin · BAVENCIO · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · CABOMETYX · CALQUENCE · CINQAIR · CINVANTI · COSELA · CYRAMZA · Cabometyx · Cinvanti · DARZALEX · DIS Navify Software · Doptelet · ELIGARD · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · EVENITY · Enhertu · FARYDAK · FASLODEX · FERAHEME · FOTIVDA · FOUNDATIONONE · GAVRETO · GILOTRIF · Halaven · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Idhifa · Imbruvica · Inrebic · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRYSTEXXA · Kyprolis · LENVIMA · LIBTAYO · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MARGENZA · MEKINIST · MONJUVI · NERLYNX · NINLARO · Nerlynx · Neulasta · NovoTTF-100L · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ODOMZO · ONUREG · OPDIVO · ORGOVYX · Ogivri · Oncology · PADCEV · PIQRAY · POTELIGEO · PROMACTA · Perjeta · QUZYTTIR · REBLOZYL · RYBREVANT · RYDAPT · Reblozyl · Revlimid · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TUKYSA · Tavalisse · Trodelvy · Truxima · UKONIQ · ULTOMIRIS · Udenyca · VARUBI · VENCLEXTA · VERZENIO · VYXEOS · Vitrakvi · XALKORI · XARELTO · XGEVA · XOSPATA · XTANDI · Xermelo · Xofigo · Yescarta · ZEJULA · ZOLADEX · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a hematology & oncology specialist in Jersey City?
Compare hematology & oncology specialists in the Jersey City area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
735
Per 100K population
103.5
County median income
$90,032
Nearest hospital
JERSEY CITY MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Zarubin is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Zarubin experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Zarubin performed 183 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Zarubin receive payments from pharmaceutical companies?
Yes. Dr. Zarubin received a total of $9,674 from 73 companies across 593 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Zarubin's costs compare to other hematology & oncology specialists in Jersey City?
Dr. Zarubin's average Medicare payment per service is $89. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Zarubin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →